C12N 2710/20071
Demonstrated in vivo effect
C12N2710/20071 (Demonstrated in vivo effect) appears on 58 US grants and 96 published applications in this corpus.
Search patents in C12N- Granted patents
- 58
- Published applications
- 96
- Assignees
- 53
- Inventors
- 191
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 2 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 4 |
| 2012 | 2 | 3 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 4 | 8 |
| 2016 | 2 | 8 |
| 2017 | 5 | 10 |
| 2018 | 7 | 11 |
| 2019 | 7 | 5 |
| 2020 | 3 | 6 |
| 2021 | 8 | 10 |
| 2022 | 3 | 5 |
| 2023 | 8 | 11 |
| 2024 | 1 | 8 |
| 2025 | 3 | 1 |
| 2026 | 4 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cell capable of activating immune system, and pharmaceutical composition containing said cell11 Aug 2026US 12,703,867 B2Riken
- Thermostable lipid nanoparticle and methods of use thereof4 Aug 2026US 12,697,308 B2Merck Sharp & Dohme Corp.
- HPV vaccine7 Jul 2026US 12,673,103 B2Merck Sharp & Dohme Corp.
- Methods for treating bladder tumors with viral nanoparticle conjugates and immune checkpoint inhibitors31 Mar 2026US 12,589,165 B2Aura Biosciences, Inc.
- Vaccines for recurrent respiratory papillomatosis and methods of using the same25 Nov 2025US 12,478,667 B2Inovio Pharmaceuticals, Inc.
- Vaccines For Recurrent Respiratory Papillomatosis And Methods Of Using The Same26 Feb 2026US 2026/0053908 A1Inovio Pharmaceuticals, Inc.
- Messenger ribonucleic acids for enhancing immune responses and methods of use thereof29 May 2025US 2025/0170235 A1ModernaTX, Inc.
- Compositions, methods and uses for thermally stable multi-targeted antigens11 Jul 2024US 2024/0226015 A9The Regents of the University of Colorado, a body corporate
- Universal vaccine platform4 Jul 2024US 2024/0216502 A1Arizona Board of Regents on behalf of Arizona State University
- Compositions, methods and uses for thermally stable multi-targeted antigens25 Apr 2024US 2024/0130973 A1The Regents of the University of Colorado, a body corporate
Most cited
By later US patents
- Sexually transmitted disease vaccines86US 10,493,143 B2ModernaTX, Inc. · 2019
- Adenoviral expression vector comprising a CD40L fusion protein adapted to elicit cellular immunity25US 8,119,117 B2VAXum, LLC · 2012
- HPV16 non HLA-restricted t-cell vaccines, compositions and methods of use thereof8US 11,401,306 B2PDS Biotechnology Corporation · 2022
- Recombinant protein bodies as immunogen-specific adjuvants8US 9,555,097 B2Era Biotech, S.A. · 2017
- Method of obtaining thermostable dried vaccine formulations8US 9,782,470 B2Merck Sharp & Dohme Corp. · 2017